Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Mallinckrodt
Baxter
Moodys

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Levonordefrin; mepivacaine hydrochloride - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for levonordefrin; mepivacaine hydrochloride and what is the scope of freedom to operate?

Levonordefrin; mepivacaine hydrochloride is the generic ingredient in six branded drugs marketed by Solvay, Eastman Kodak, Septodont Inc, Belmora Llc, Dentsply Pharm, and Deproco, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for levonordefrin; mepivacaine hydrochloride. One supplier is listed for this compound.

Summary for levonordefrin; mepivacaine hydrochloride
Recent Clinical Trials for levonordefrin; mepivacaine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Sao PauloN/A
Novalar Pharmaceuticals, Inc.Phase 2

See all levonordefrin; mepivacaine hydrochloride clinical trials

Pharmacology for levonordefrin; mepivacaine hydrochloride
Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia

US Patents and Regulatory Information for levonordefrin; mepivacaine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Deproco SCANDONEST L levonordefrin; mepivacaine hydrochloride INJECTABLE;INJECTION 088388-001 Oct 10, 1984 RX No Yes   Start Trial   Start Trial   Start Trial
Eastman Kodak CARBOCAINE W/ NEO-COBEFRIN levonordefrin; mepivacaine hydrochloride INJECTABLE;INJECTION 012125-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Belmora Llc MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN levonordefrin; mepivacaine hydrochloride INJECTABLE;INJECTION 084850-002 Oct 21, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Septodont Inc ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN levonordefrin; mepivacaine hydrochloride INJECTABLE;INJECTION 084697-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Solvay ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN levonordefrin; mepivacaine hydrochloride INJECTABLE;INJECTION 085010-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Dentsply Pharm POLOCAINE W/ LEVONORDEFRIN levonordefrin; mepivacaine hydrochloride INJECTABLE;INJECTION 089517-001 Apr 14, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Johnson and Johnson
Colorcon
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.